[Eptifibatide blocks the increase in C-reactive protein concentration after coronary angioplasty].
We measured C-reactive protein concentrations in 31 patients with interventional procedures after blocking thrombosis in 17 of them by the administration of a 12 hour long infusion of eptifibatide in order to evaluate the role of arterial thrombosis. There were no differences in C reactive protein concentration between the treated and control group pre-angioplasty (0.32 0.4 vs 0.56 0.57 md/dl; p = NS), nor post-angioplasty (0.35 0.42 vs 0.53 0.5 mg/dl, p = Ns). The eptifibatide group maintained basal C reactive protein concentrations 6 hours after the procedure, while the control group had a significant increase (0.43 0.5 vs 1.02 0.89 mg/dl; p < 0.05). There was a decrease in C reactive protein 24 hours after angioplasty in eptifibatide group (0.24 0.27 vs 1.34 0.89 mg/dl; p < 0.001), but it increased again 48 hours after the procedure although to a lesser extent than in the control group (0.57 0.55 vs 2.18 2.1 mg/dl; p < 0.05). Eptifibatide, a synthetic peptide which is a selective blocker of the platelet GP IIb/IIIa receptor significantly reduced C-reactive protein concentration after angioplasty.
Merino Otermin
Alvaro
A
Instituto Cardiológico, Clínica Rotger, Palma de Mallorca, Spain. amerino@clinicarotger.es
Artaiz Urdaci
Miguel
M
Bergadá García
Jaume
J
Riera Sagrera
María
M
Vidal Salvá
Bernat
B
Rodríguez Fernández
Antonio
A
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D002097:C-Reactive Protein / Q000032:analysis* / Q000187:drug effects; D003327:Coronary Disease / Q000097:blood* / Q000628:therapy*; D000077542:Eptifibatide; D006801:Humans; D008875:Middle Aged; D010455:Peptides / Q000494:pharmacology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011446:Prospective Studies
D010455:Peptides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D002097:C-Reactive Protein; D000077542:Eptifibatide